The response of CCLs with Asian ancestry is consistent with previous studies reporting a high susceptibility of Asian patient-derived cell lines to combination treatment with nimotuzumab (EGFR inhibitor) and rapamycin (mTOR inhibitor) in GBM, which was found to be independent of their EGFR status [23]. This evidence concerns the gene MTOR and glioblastoma.